NCT05527288View on ClinicalTrials.gov

A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 28, 2021

Primary Completion Date

September 12, 2021

Study Completion Date

September 12, 2021

Conditions
Alzheimer DiseaseDementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental Disorders
Interventions
DRUG

Drug: [18F]florbetaben

All eligible patients will receive a single administration of the imaging agent \[18F\]florbetaben at a radioactive dose of 300 MBq.

Trial Locations (1)

100039

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Sinotau Pharmaceutical Group

INDUSTRY

NCT05527288 - A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population | Biotech Hunter | Biotech Hunter